Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1999 February; 79(5-6): 858–864.
PMCID: PMC2362673

The influence on survival of delay in the presentation and treatment of symptomatic breast cancer


The aim of this study was to examine the possible influence on survival of delays prior to presentation and/or treatment among women with breast cancer. Duration of symptoms prior to hospital referral was recorded for 2964 women who presented with any stage of breast cancer to Guy's Hospital between 1975 and 1990. Median follow-up is 12.5 years. The impact of delay (defined as having symptoms for 12 or more weeks) on survival was measured from the date of diagnosis and from the date when the patient first noticed symptoms to control for lead-time bias. Thirty-two per cent (942/2964) of patients had symptoms for 12 or more weeks before their first hospital visit and 32% (302/942) of patients with delays of 12 or more weeks had locally advanced or metastatic disease, compared with only 10% (210/2022) of those with delays of less than 12 weeks (P< 0.0001). Survival measured both from the date of diagnosis (P< 0.001) and from the onset of the patient's symptoms (P= 0.003) was worse among women with longer delays. Ten years after the onset of symptoms, survival was 52% for women with delays less than 12 weeks and 47% for those with longer delays. At 20 years the survival rates were 34% and 24% respectively. Furthermore, patients with delays of 12–26 weeks had significantly worse survival rates than those with delays of less than 12 weeks. Multivariate analyses indicated that the adverse impact of delay in presentation on survival was attributable to an association between longer delays and more advanced stage. However, within individual stages, longer delay had no adverse impact on survival. Analyses based on ‘total delay’ (i.e. the interval between a patient first noticing symptoms and starting treatment) yielded very similar results in terms of survival to those based on delay to first hospital visit (delay in presentation). © 1999 Cancer Research Campaign

Keywords: breast cancer, delay, duration of symptoms, survival

Full Text

The Full Text of this article is available as a PDF (99K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Afzelius P, Zedeler K, Sommer H, Mouridsen HT, Blichert-Toft M. Patient's and doctor's delay in primary breast cancer. Prognostic implications. Acta Oncol. 1994;33(4):345–351. [PubMed]
  • Alderson MR, Hamlin I, Staunton MD. The relative significance of prognostic factors in breast carcinoma. Br J Cancer. 1971 Dec;25(4):646–656. [PMC free article] [PubMed]
  • BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. [PMC free article] [PubMed]
  • Burgess CC, Ramirez AJ, Richards MA, Love SB. Who and what influences delayed presentation in breast cancer? Br J Cancer. 1998 Apr;77(8):1343–1348. [PMC free article] [PubMed]
  • Charlson ME. Delay in the treatment of carcinoma of the breast. Surg Gynecol Obstet. 1985 May;160(5):393–399. [PubMed]
  • Dennis CR, Gardner B, Lim B. Analysis of survival and recurrence vs. patient and doctor delay in treatment of breast cancer. Cancer. 1975 Mar;35(3):714–720. [PubMed]
  • Elwood JM, Moorehead WP. Delay in diagnosis and long-term survival in breast cancer. Br Med J. 1980 May 31;280(6227):1291–1294. [PMC free article] [PubMed]
  • Facione NC. Delay versus help seeking for breast cancer symptoms: a critical review of the literature on patient and provider delay. Soc Sci Med. 1993 Jun;36(12):1521–1534. [PubMed]
  • Feldman JG, Saunders M, Carter AC, Gardner B. The effects of patient delay and symptoms other than a lump on survival in breast cancer. Cancer. 1983 Apr 1;51(7):1226–1229. [PubMed]
  • Fentiman IS, Howell A, Hamed H, Lee SM, Ranson M, Wall J, Chaudary MA, Ash CM, Gregory WM, Sellwood RA, et al. A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. Br J Cancer. 1994 Oct;70(4):729–731. [PMC free article] [PubMed]
  • Fisher ER, Redmond C, Fisher B. A perspective concerning the relation of duration of symptoms to treatment failure in patients with breast cancer. Cancer. 1977 Dec;40(6):3160–3167. [PubMed]
  • Huguley CM, Jr, Brown RL, Greenberg RS, Clark WS. Breast self-examination and survival from breast cancer. Cancer. 1988 Oct 1;62(7):1389–1396. [PubMed]
  • Kern KA. Medicolegal analysis of the delayed diagnosis of cancer in 338 cases in the United States. Arch Surg. 1994 Apr;129(4):397–404. [PubMed]
  • Machiavelli M, Leone B, Romero A, Perez J, Vallejo C, Bianco A, Rodriguez R, Estevez R, Chacon R, Dansky C, et al. Relation between delay and survival in 596 patients with breast cancer. Oncology. 1989;46(2):78–82. [PubMed]
  • MacArthur C, Smith A. Delay in breast cancer and the nature of presenting symptoms. Lancet. 1981 Mar 14;1(8220 Pt 1):601–603. [PubMed]
  • Neave LM, Mason BH, Kay RG. Does delay in diagnosis of breast cancer affect survival? Breast Cancer Res Treat. 1990 Feb;15(2):103–108. [PubMed]
  • Raabe NK, Fossaa SD. Primary invasive breast carcinoma in Oslo 1980-1989. Incidence and delay. Acta Oncol. 1996;35(1):9–15. [PubMed]
  • Richards MA, O'Reilly SM, Howell A, George WD, Fentiman IS, Chaudary MA, Crowther D, Rubens RD. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol. 1990 Dec;8(12):2032–2039. [PubMed]
  • Richardson JL, Langholz B, Bernstein L, Burciaga C, Danley K, Ross RK. Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer. 1992 Jun;65(6):922–926. [PMC free article] [PubMed]
  • Rossi S, Cinini C, Di Pietro C, Lombardi CP, Crucitti A, Bellantone R, Crucitti F. Diagnostic delay in breast cancer: correlation with disease stage and prognosis. Tumori. 1990 Dec 31;76(6):559–562. [PubMed]
  • Rubens RD, Armitage P, Winter PJ, Tong D, Hayward JL. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer. 1977 Aug;13(8):805–811. [PubMed]
  • Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL. Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer. 1980 Mar;16(3):351–356. [PubMed]
  • Rubens RD, Hayward JL, Knight RK, Bulbrook RD, Fentiman IS, Chaudary M, Howell A, Bush H, Crowther D, Sellwood RA, et al. Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet. 1983 Apr 16;1(8329):839–843. [PubMed]
  • Rubens RD, Bartelink H, Engelsman E, Hayward JL, Rotmensz N, Sylvester R, van der Schueren E, Papadiamantis J, Vassilaros SD, Wildiers J, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol. 1989 Apr;25(4):667–678. [PubMed]
  • Sheridan B, Fleming J, Atkinson L, Scott G. The effects of delay in treatment of survival rates in carcinoma of the breast. Med J Aust. 1971 Jan 30;1(5):262–267. [PubMed]
  • Vernon SW, Tilley BC, Neale AV, Steinfeldt L. Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancer. Cancer. 1985 Apr 1;55(7):1563–1571. [PubMed]
  • Wallgren A, Silfverswärd C, Eklund G. Prognostic factors in mammary carcinoma. Acta Radiol Ther Phys Biol. 1976 Feb;15(1):1–16. [PubMed]
  • Wilkinson GS, Edgerton F, Wallace HJ, Jr, Reese P, Patterson J, Priore R. Delay, stage of disease and survival from breast cancer. J Chronic Dis. 1979;32(5):365–373. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK